Sankalp Speciality Healthcare

Clinical Research

The Research group of Sankalp Speciality Hospital is young strong headed panel of super specialist working in the area of Nashik and north Maharashtra region. The group is headed by Dr. Bhushan Nemade (MD, PDCR) who himself is Oncologist working in the field of research for more than 8-10 years.

The entire group is committed to conduct Clinical research according to ICH GCP and ICMR guidelines.


Our Mission

To facilitate quality clinical research for effective and efficient evaluation of new pharmaceutical investigational product.


Scope of Services

  • Protocol Development and Professional guidance in following Specialties
    1. Medical oncology
    2. Radiation Oncology
    3. Surgical oncology
    4. Pediatric Oncology
    5. Hematology.
    6. Orthopedics
    7. Plastic surgery
    8. Trauma
    9. General and Laparoscopic surgery.
    10. Neurology
    11. Pulmonology/respiratory Medicine.
  • To conduct Phase I to Phase IV studies in all the specialties mentioned above.
  • To facilitate quality clinical research for effective and efficient evaluation of new pharmaceutical investigational product.
  • Focus on Quality, Ethics and Well-being of the clinical trial subject
  • Provides supervision & co-ordination for clinical researchers to ensure the timely Initiation, Execution and Delivery of clinical trial projects.
  • Provides quality assurance services that result in authentic, verifiable and accurate data.

 


Panel Of Investigators


  • Dr. Bhushan Nemade
    (MD, PDCR, Clinical Oncology)
  • Dr. Chandrashekhar Pethe
    (DM , Medical Oncology)
  • Dr. Nagesh Madnoorkar
    (MS DNB Surgical Oncology)
  • Dr. Ajay Jadhav
    (MCh Surgical Oncology)
  • Dr. Sanjay Ahire
    (MS Surgical Oncologist)
  • Dr. Sulabhchandra Bhamare
    (MS, DNB, Surgical Oncology)
  • Dr. Vinayak Shendage
    (MS, DNB, Surgical Oncology)
  • Dr. Tushar Patil
    (MS Surgical Oncologist)
  • Dr. Satish Sonawane
    (MS Surgical Oncologist)
  • Dr. Bhushan Nikam
    (MD Radiation Oncology)
  • Dr. Rohan Kharde
    (MD Radiation Oncology)
  • Dr. Sachin Ingale
    (MS Surgical Oncologist)
  • Dr. Ateesh Borole
    (MCh Plastic and Reconstructive Surgery)
  • Dr. Sachin Patil
    (MS Orthopedics)
  • Dr. Harshad Mahatme
    (MS FIAGES General / Lap Surgeon)
  • Dr.Goukl Endait
    (MD Pulmonology, Respiratory Medicine)
  • Dr. Satish Kapadnis
    (MCh Pediatric Surgery)

 


Research Profile


Ongoing Studies

Breast
A Prospective, Multicenter, Randomized, Double-blind, Parallel group Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when Given in Combination with Paclitaxel in Patients Diagnosed with HER2 Positive Metastatic Breast Cancer.

Lymphoma/ Leukaemia
Open Label Randomized study of two different rituximab as monotherapy of CD 20 positive indolent Non Hodgkin Lymphoma.

Prostate Cancer
Phase II Study of Masatinib with Docetexel in hormone Refractory Prostate Cancer

Pancreatic/Hepatobiliary
Phase III Study of Masatinib in combination with gemcitabine to gemcitabine with placebo followed by second line treatment by masitinb in combination with FOLFIRI 3 vs placebo in combination with FOLFIRI 3 in treatment of patients with non resectable locally advanced or metastatic Ca pancreas.

Colorectal
A prospective, multicenter, randomized, double blind, placebo-controlled,2-parallel groups, phase 3 study to compare the efficacy and safety of(masitinib in combination with irinotecan, 5-fluorouracil and folinic acid (FOLFIRI)) to (placebo in combination with FOLFIRI) in second line treatment of patients with metastatic colorectal cancer.

A randomised double-blind study Comparing two humanized monoclonal antibodies that target VEGF incombination with mFOLFOX6 in patients with non-resectable metastatic colorectalcancer (mCRC)

Head Neck
Phase I study of cetuximab compared with Innovator in locally advanced Head beck cancer not fit for radical chemoradiation.

Lung
A randomised double-blind study Comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC).


• Site and DCGI approval of studies

• Ethics Committee

• ICH GCP guidelines

• ICMR guidelines

• CDSCO/DCGI – clinical trial page

24/7 help line no

0253-2319242

Our Department

The Hospital functions with a strong mission of quality healthcare at affordable prices and provides advanced Healthcare services...

View Details